4584.T
Kidswell Bio Corporation
グロース · 医薬品 · 医薬品 · JP
JPY 161.00
−3.59%Year over year
Reported trailing growth
- Revenue
- +81.1%
- EBITDA
- —
- EBIT
- +130.8%
- EPS
- +105.1%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- -43.4%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +48.0%
- EBITDA
- +102.1%
- EBIT
- +102.0%
- Net income
- +98.5%
- EPS
- +98.7%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026